Plasma proteins as biomarkers for diagnosis of STEMI with hypertension and application

By detecting the specific protein marker CA1 in plasma, and utilizing Olink PEA technology and machine learning models, the problem of insufficient early identification and risk assessment in STEMI patients with hypertension has been solved, achieving efficient and accurate early diagnosis and personalized assessment.

CN122128427APending Publication Date: 2026-06-02NINGBO FIRST HOSPITAL
View PDF 3 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
NINGBO FIRST HOSPITAL
Filing Date
2026-05-06
Publication Date
2026-06-02

AI Technical Summary

Technical Problem

Existing technologies are insufficient for rapid and accurate early identification and risk assessment in STEMI patients with hypertension. The lack of specific biomarkers and combinations of multi-protein biomarkers leads to inadequate diagnostic and intervention strategies.

Method used

By detecting the specific protein marker CA1 in plasma, high-throughput proteomics analysis was performed using Olink PEA technology. Combined with machine learning models, a diagnostic model was constructed to screen out plasma protein markers with high specificity and stability for the early diagnosis of STEMI complicated with hypertension.

Benefits of technology

It enables early diagnosis and personalized assessment of STEMI combined with hypertension, improves detection efficiency and accuracy, is suitable for screening high-risk and potentially at-risk populations, reduces detection costs, and is suitable for use in primary healthcare units.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122128427A_ABST
    Figure CN122128427A_ABST
Patent Text Reader

Abstract

This invention discloses a plasma protein as a biomarker for diagnosing STEMI complicated with hypertension and its application. The characteristic is that the plasma protein biomarker is CA1, which can be used in the preparation of products for diagnosing STEMI complicated with hypertension. The advantage is that STEMI complicated with hypertension can be diagnosed at an early stage by measuring the plasma protein biomarker, providing an effective tool for the diagnosis of STEMI complicated with hypertension, with high detection efficiency and strong targeting.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS

    CN108348607A

  • Related protein marker for assisting early diagnosis of acute myocardial infarction and application thereof

    CN120610019A

  • Application of protein marker CA1 in preparation of myocardial infarction early diagnosis reagent or kit

    CN121347820A